SONIRE Therapeutics Inc.
PrivateLast Round
Grant
Jun 17, 2026
Est. Valuation
$37.05M
Total Funding Raised
$53.22M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
SONIRE Therapeutics Inc. operates in Healthcare & Life Sciences and is based in Palo Alto, California. Its latest recorded funding round was a Grant round in June 2026.
SONIRE Therapeutics Inc. is a clinical-stage medical device company that develops next-generation ultrasound-guided high-intensity focused ultrasound (HIFU) therapy systems for the non-invasive treatment of solid tumors, with an initial focus on pancreatic cancer.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Medical Imaging, Clinical Trials
Business Model
B2B
Customer Profile
Hardware Sales
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
SONIRE Therapeutics Inc. Comparables
Compare SONIRE Therapeutics Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Petal Surgical | 88% | |
| Alpheus Medical | 80% | |
| IMGT Co., Ltd. | 78% |
For institutional investors. Book with your work email.
SONIRE Therapeutics Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Jun 17, 2026 | ||||
| Series A | Apr 15, 2026 | ||||
| Series B | Dec 23, 2022 | ||||
| Series A | Jun 11, 2021 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
SONIRE Therapeutics Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| QR Investment Co., Ltd. | Series B |
| スパークル株式会社 | Series A |
| Higin Capital | Series A, Series B |
| New Energy and Industrial Technology Development Organization | Grant |
| Japan Growth Capital | Series B |
| Nissay Capital | Series B |
| Daiwa Corporate Investment Co., Ltd. | Series B |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 24, 2026
Monthly visitors increased 49% MoM.
- Jun 17, 2026
$13M grant from New Energy and Industrial Technology Development Organization.
For institutional investors. Book with your work email.
SONIRE Therapeutics Inc. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about SONIRE Therapeutics Inc.'s valuation, stock price, and market status.
Is SONIRE Therapeutics Inc. a public or private company?
SONIRE Therapeutics Inc. is a private company.
What is the current stock price of SONIRE Therapeutics Inc.?
SONIRE Therapeutics Inc. is a private company, so its shares have no public market price. Caplight tracks SONIRE Therapeutics Inc.'s secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is SONIRE Therapeutics Inc. worth (valuation)?
SONIRE Therapeutics Inc.'s valuation is estimated at $37.0M based on funding round data.
Can I buy SONIRE Therapeutics Inc. stock?
SONIRE Therapeutics Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was SONIRE Therapeutics Inc.'s last funding round?
SONIRE Therapeutics Inc.'s most recent funding round was Grant on June 17, 2026.
Who are the main investors in SONIRE Therapeutics Inc.?
Key investors in SONIRE Therapeutics Inc. include Santé Ventures, Fast Track Initiative.
Will SONIRE Therapeutics Inc. IPO soon?
No public IPO plans have been announced for SONIRE Therapeutics Inc..
How can I track SONIRE Therapeutics Inc. secondary market activity?
Caplight tracks bids, offers, and trades in SONIRE Therapeutics Inc.'s shares on secondary markets.